Evidence map›Paper›PMID 41120096›Full record

ArticleThoracic cancer2025

Acquired MTAP Loss Following Entrectinib Resistance in ROS1-Rearranged NSCLC With CD74 Exon 3-ROS1 Exon 34 Fusion.

Mizuha Haraguchi Hashiguchi, Maika Tanino, Suzuyuki Yoneda, Masato Asaoka, Junko Kagyo, Makoto Katayama, Hideki Terai, Kohei Nakamura, Hiroshi Nishihara, Koichi Fukunaga

Abstract readCase ReportsLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mizuha Haraguchi HashiguchiDivision of Pulmonary Medicine, Department of Medicine, Keiyu Hospital, Yokohama, Japan.ORCID https://orcid.org/0000-0002-4698-1655
Maika TaninoDivision of Pulmonary Medicine, Department of Medicine, Keiyu Hospital, Yokohama, Japan.
Suzuyuki YonedaDivision of Pulmonary Medicine, Department of Medicine, Keiyu Hospital, Yokohama, Japan.
Masato AsaokaDivision of Pulmonary Medicine, Department of Medicine, Keiyu Hospital, Yokohama, Japan.
Junko KagyoDivision of Pulmonary Medicine, Department of Medicine, Keiyu Hospital, Yokohama, Japan.
Makoto KatayamaDepartment of Neurosurgery, Kawasaki Municipal Hospital, Kawasaki, Japan.
Hideki TeraiDivision of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Tokyo, Japan.
Kohei NakamuraCenter for Cancer Genomics, Keio University School of Medicine, Tokyo, Japan.
Hiroshi NishiharaCenter for Cancer Genomics, Keio University School of Medicine, Tokyo, Japan.
Koichi FukunagaDivision of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This case highlights acquired MTAP loss during disease progression in ROS1-rearranged NSCLC. Despite persistent CD74-ROS1 fusion and absence of known resistance mutations, the patient developed CNS progression after entrectinib, underscoring the value of longitudinal genomic profiling in guiding treatment decisions.

Indexed as

Antigens, Differentiation, B-LymphocyteBenzamidesCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmHistocompatibility Antigens Class IIIndazolesLung NeoplasmsOncogene Proteins, FusionProtein-Tyrosine KinasesProto-Oncogene ProteinsExonsGene RearrangementHumansAntigens, Differentiation, B-LymphocyteBenzamidesentrectinibHistocompatibility Antigens Class IIIndazolesinvariant chainOncogene Proteins, FusionProtein-Tyrosine KinasesProto-Oncogene ProteinsROS1 protein, human

Identifiers

PMID41120096
PMCPMC12539904

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.